Currax Pharmaceuticals LLC ("Currax") spotlights the publication of a new peer‑reviewed obesity treatment article, "Targeting Multiple Gut‑Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy," in Obesity Science and Practice.

The article makes a compelling scientific case for combination approaches in obesity pharmacotherapy, highlighting the complex interplay between multiple gut‑brain pathways involved in energy regulation, appetite, and metabolic control. Drawing on existing evidence, the authors make the case that targeting multiple biological mechanisms offers a more comprehensive therapeutic strategy for managing obesity.

Obesity Science and Practice, a peer‑reviewed journal jointly published by The Obesity Society and the World Obesity Federation, reaches a global audience of clinicians and researchers across obesity medicine and metabolic health. The publication reflects and reinforces the accelerating shift toward evidence-based, mechanistically informed approaches to obesity treatment.

"The heterogeneity of obesity demands a more personalized approach to obesity treatment selection," said Michael Kyle MD, Chief Medical Officer Currax Pharmaceuticals. "This review reinforces the importance of considering biological drivers beyond weight alone, particularly in patients who struggle with cravings or hedonic eating despite adequate satiety."

Together, the findings reinforce a growing scientific consensus that obesity is driven by interconnected biological pathways, and that effective long‑term obesity management requires multifaceted, individualized treatment strategies grounded in underlying biology rather than weight alone.

About Currax

Currax is a specialty pharmaceutical company that pursues transformative therapies for chronic conditions like obesity. Combining innovative advancements with compassionate care, Currax delivers therapies that are designed to inspire hope and offer life-changing outcomes. Currax's flagship product, CONTRAVE® (naltrexone HCl/bupropion HCl), reflects the company's commitment to provide therapies that offer unmatched versatility and utility. Learn more at www.curraxpharma.com

About CONTRAVE:

CONTRAVE®, is an extended-release fixed dose combination of naltrexone and bupropion (naltrexone HCl/bupropion HCl) indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or who are overweight in the presence of at least one weight-related comorbid condition. For full Prescribing Information, including BOXED WARNING and Medication Guide, please visit www.contrave.com.